Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Fase I-onderzoek naar IL-10-producerende anti-CD19 CAR T-cellen bij r/r B-cel ALL
dec 2025 | Leukemie